title: Boron neutron capture irradiation: setting up a clinical programme in Nice.
abstract: Neutron capture irradiation aims to selectively destroy tumor cells using 10B(n,alpha)7Li nuclear reactions produced within themselves. Following the capture reaction, an alpha particle and a, 7Li ion are emitted. Carrying an energy of 2.79 MeV, they destroy all molecular structures along their path close to 10 microns. These captures, used exclusively with a 'slow' neutron irradiation, provide a neutron capture therapy (BNCT). If they are used in addition to a fast neutron beam irradiation, they provide a neutron capture potentiation (NCP). The Centre Antoine-Lacassagne in Nice is actively involved in the European Demonstration Project for BNCT of grade IV glioblastomas (GBM) after surgical excision and BSH administration. Taking into account the preliminary results obtained in Japan, work on an 'epithermal' neutron target compatible with various cyclotron beams is in progress to facilitate further developments of this technique. For NCP, thermalized neutron yield has been measured in phantoms irradiated in the fast neutron beam of the biomedical cyclotron in Nice. A thermal peak appears after 5 cm depth in the tissues, delayed after the fast neutron peak at 1.8 cm depth. Thus, a physical overdosage of 10% may be obtained if 100 ppm of 10B are assumed in the tissues. Our results using CAL 58 GBM cell line demonstrate a dose modification factor (DMF) of 1.19 when 100 ppm of boric acid are added to the growth medium. Thus for the particles, issued from neutron capture, a biological efficiency at least twice that of fast neutrons can be derived. These results, compared with historical data on fast neutron irradiation of glioblastoma, suggest that a therapeutic window may be obtained for GBM.
authors.affiliation: Centre Antoine-Lacassagne, Cyclotron Biomédical, Nice, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Pignol
authors.forename: P
authors.initials: P
authors.lastname: Chauvel
authors.forename: P
authors.initials: P
authors.lastname: Paquis
authors.forename: A
authors.initials: A
authors.lastname: Courdi
authors.forename: N
authors.initials: N
authors.lastname: Iborra-Brassart
authors.forename: M
authors.initials: M
authors.lastname: Lonjon
authors.forename: C
authors.initials: C
authors.lastname: Lebrun-Frenay
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: P
authors.initials: P
authors.lastname: Grellier
authors.forename: M
authors.initials: M
authors.lastname: Chatel
authors.forename: J
authors.initials: J
authors.lastname: Hérault
authors.forename: R J
authors.initials: RJ
authors.lastname: Bensadoun
authors.forename: G
authors.initials: G
authors.lastname: Milano
authors.forename: F
authors.initials: F
authors.lastname: Nepveu
authors.forename: J P
authors.initials: JP
authors.lastname: Patau
authors.forename: F
authors.initials: F
authors.lastname: Demard
authors.forename: N
authors.initials: N
authors.lastname: Breteau
mesh_terms: D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy; D002470:Cell Survival / Q000528:radiation effects; D017357:Cyclotrons; D004307:Dose-Response Relationship, Radiation; D005214:Fast Neutrons; D005602:France; D005909:Glioblastoma / Q000532:radiotherapy; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D019047:Phantoms, Imaging; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000379:methods*; D014407:Tumor Cells, Cultured